Addex raises $2.8 million via ATM offering, extends cash runway to Q4 2027

Addex Therapeutics announced on August 26, 2026 that it had raised gross proceeds of USD 2.8 million (CHF 2.2 million) through the sale of 437,869 ADSs representing 52,544,280 shares, through its At the Market (ATM) offering agreement with H.C. Wainwright & Co.¹

The company said that following the sale of these ADSs, its cash runway has been extended to the fourth quarter of 2027.¹ As a result of the transaction, the outstanding share count, excluding treasury shares, rose to 210,292,217, while total issued shares stayed at 218,654,496.¹

Addex describes itself as a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders.¹ Its lead program, dipraglurant, an mGlu5 negative allosteric modulator, is being evaluated for potential future development in recovery from brain injury, including after stroke and traumatic brain injury.¹

The company also noted that its partner Indivior has selected a GABAB PAM candidate for development in substance use disorders and has completed IND-enabling studies¹, while Addex is separately advancing its own GABAB PAM program for chronic cough.¹

On its broader pipeline, Addex said it owns a 20% equity stake in Neurosterix US Holdings LLC, a private spin-out advancing allosteric modulator programs, including an M4 PAM candidate for schizophrenia, psychosis and mood-related disorders, and an mGlu7 NAM candidate for mood disorders.¹ The company also disclosed that it has invested in Stalicla, a private Swiss company working on precision medicine approaches for neurodevelopmental and neuropsychiatric disorders.¹

Addex shares trade on the SIX Swiss Exchange, with ADSs listed on Nasdaq under the ticker ADXN.